Biologics Spine Top Stories Biocomposites’ investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2 byJosh SandbergJanuary 4, 2024
Biologics Financial Biocomposites invests in Renovos Biologics – developers of the RENOVITE® nanoclay therapeutic delivery platform byJosh SandbergJuly 6, 2023
